Abstract
Objectives:
Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established.
Design:
Data of 330 consecutive pregnancies with IBD was prospectively collected.
Results:
Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's disease patients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy.
Discussion:
Although further study is needed, VDZ appears of low risk during pregnancy.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Cohort Studies
-
Crohn Disease / diagnosis
-
Crohn Disease / drug therapy
-
Female
-
Gastrointestinal Agents / administration & dosage
-
Gastrointestinal Agents / adverse effects
-
Humans
-
Infant, Newborn
-
Inflammatory Bowel Diseases / diagnosis
-
Inflammatory Bowel Diseases / drug therapy*
-
Patient Safety*
-
Pregnancy
-
Pregnancy Outcome*
-
Pregnancy, High-Risk
-
Prognosis
-
Prospective Studies
-
Risk Assessment
-
Tumor Necrosis Factor-alpha / therapeutic use*
Substances
-
Antibodies, Monoclonal, Humanized
-
Gastrointestinal Agents
-
Tumor Necrosis Factor-alpha
-
vedolizumab